Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS

Conclusions These findings suggest that serum AHR agonist levels negatively correlate with disability in RRMS and PMS and decrease longitudinally in correlation with MRI markers of disease progression. Thus, serum AHR agonistic activity may serve as novel biomarker for disability progression in MS.

http://nn.neurology.org/cgi/content/short/8/2/e933?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - December 24, 2020 Category: Neurology Authors: Tsaktanis, T., Beyer, T., Nirschl, L., Linnerbauer, M., Grummel, V., Bussas, M., Tjon, E., Mühlau, M., Korn, T., Hemmer, B., Quintana, F. J., Rothhammer, V. Tags: All Immunology, Autoimmune diseases, Prognosis, Multiple sclerosis Article Source Type: research